Concall Intelligence

Man Industries reported robust performance in Q1 FY27 with consolidated EBITDA reaching a record INR155 crores (up 92.6% YoY) and stand-alone PAT more than doubling YoY, driven by optimized product and geographic mix. Management maintains an optimistic outlook underpinned by a structural multiyear demand cycle across MENA, GCC, and Southeast Asia, along with strategic capacity additions in Saudi Arabia (NPC acquisition, Dammam coating facility) and Jammu (stainless steel proj

Cochin Shipyard reported stable performance for Q1 FY27 with a turnover of INR 1,094.21 crores, PBT of INR 202.49 crores, and PAT of INR 151.45 crores. Management maintains a positive long-term growth outlook supported by a robust order book of INR 22,000 crores, expansion into ship repair and hybrid shipbuilding facilities, and strategic international partnerships despite execution dependencies and working capital pressures.

Karamtara Engineering Limited delivered a strong first quarterly performance as a listed company for Q1 FY27, reporting 72% YoY revenue growth to INR1,581 crores and 45% YoY PAT growth to INR87 crores, driven by robust renewable demand and international expansion.

Eppeltone Engineers Limited held its 23rd AGM discussing strategic progress, new manufacturing infrastructure, and order book health despite temporary weather-related execution delays.

VA Tech Wabag reported record FY 2025-26 performance with revenue of INR 3,944 Crores, EBITDA of INR 524 Crores, and PAT of INR 371 Crores, supported by a robust order book exceeding INR 17,200 Crores and a net cash positive position for the sixth consecutive year.

Granules India Limited reported returning to growth in FY26 after three years of flat performance, backed by a strong net cash position following preferential warrants in September 2026. The company is executing a strategic transformation focusing on four growth engines (controlled substances, complex generics/early market opportunities, oncology, and peptide CDMO) while funding a 2,000 crore organic capex plan over the next 3 to 4 years.

Steamhouse India Limited delivered robust operational performance for Q1 FY27, driven by strong growth in steam volumes and operating leverage, while completing its strategic exit from low-margin coal trading effective April 1, 2026.

RateGain reported a transformative FY26 driven by the acquisition of Sojern, significantly scaling operating revenue by 69.4% to INR1,823.6 crores. While reported PAT declined due to amortization, other income absence, and acquisition debt interest, adjusted PAT rose 19.6% to INR249.9 crores. Management successfully integrated Sojern ahead of plan, capturing $15 million in annualized cost synergies within 100 days, and has aggressively used robust free cash flow to repay 38%

Schaeffler India Limited's management highlighted robust domestic demand supported by GST 2.0 and government infrastructure spend, while maintaining a cautious approach to pure export strategies and emerging EV profitability due to low initial adoption rates.

Metro Brands Limited reported steady operational performance for FY25-26, crossing the 1,000-store milestone and posting double-digit revenue and PAT growth, though shareholders raised concerns regarding a decline in revenue per square foot and return on capital employed.

Allcargo Logistics reported a purposeful transformation year in FY2025-26, integrating express distribution and contract logistics under Vision 2030, resulting in revenue of INR 2,058 crores and a 16% growth in EBITDA to INR 233 crores.

Pakka Limited held its 46th AGM reflecting on a demanding FY 2025-26 marked by operational shutdowns, equipment breakdowns, project delays, and lower earnings, while pointing to an improving June quarter and ongoing progress on Project Jagriti for long-term growth.

Symbiotec Pharmalab reported Q1 FY27 consolidated revenue of INR 218 crores (up 7% YoY), driven mainly by the stable steroid API business. However, consolidated net profit stood lower at INR 14 crores due to a significant operational expense drag of INR 23 crores and depreciation of INR 11 crores from recently invested new businesses (biotech CDMO and complex injectables) where commercial revenues are yet to commence. Management maintains a confident revenue and EBITDA growth